Scarica l'app Stockscreener
4.15
6.53%
-0.29
Dopo l'orario di chiusura:
4.20
0.05
+1.20%
Precedente Chiudi:
$4.44
Aprire:
$4.48
Volume 24 ore:
248.97K
Relative Volume:
1.42
Capitalizzazione di mercato:
$28.04M
Reddito:
-
Utile/perdita netta:
$-21.21M
Rapporto P/E:
-0.1273
EPS:
-32.6
Flusso di cassa netto:
$-16.86M
1 W Prestazione:
+5.87%
1M Prestazione:
+18.91%
6M Prestazione:
-1.19%
1 anno Prestazione:
-1.43%
Intervallo 1D:
$4.0117
$4.48
Intervallo di 1 settimana:
$3.75
$4.48
Portata 52W:
$3.20
$6.01
Cingulate Inc Stock (CING) Company Profile
Nome
Cingulate Inc
Settore
Industria
Telefono
(913) 942-2300
Indirizzo
1901 W. 47TH PLACE, KANSAS CITY
Confronta CING con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.15 | 30.00M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | ROTH MKM | Buy |
| 2023-12-22 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Borsa (CING) Ultime notizie
Shane Schaffer reinstated as CEO of Cingulate - marketscreener.com
Cingulate reinstates Shane Schaffer as CEO, updates employment terms - Investing.com India
Cingulate Inc Reinstates Shane Schaffer as CEO - TipRanks
Cingulate Inc Equity Warrant Stock Analysis and ForecastEarnings Season Recap & Outstanding Capital Returns - earlytimes.in
Cingulate presents Phase 3 results for CTx-1301, met primary endpoint - MSN
Ascendiant Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year - MSN
Cingulate Inc. Reports Q3 2025 Financial Results - MSN
Can Cingulate Inc. Equity Warrant stock deliver surprise earnings beatMarket Growth Report & Stepwise Trade Signal Implementation - Newser
Will Cingulate Inc. stock attract more institutional investorsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - Newser
How strong is Cingulate Inc. stock balance sheetCEO Change & Accurate Intraday Trade Tips - Newser
Cingulate Inc. (NASDAQ:CING) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Dhanvantri Jeevan Rekha Limiteds Balance Sheet Supports LongTerm GrowthPrice Support Zones & Superior Wealth Building - earlytimes.in
Cingulate Inc Stock Analysis and ForecastEnergy Sector Updates & Chat With Other Investors on Daily Signals - earlytimes.in
Will Cingulate Inc. stock maintain dividend yieldEarnings Recap Summary & Precise Buy Zone Tips - moha.gov.vn
Will Cingulate Inc. stock return to pre crisis levelsPortfolio Return Summary & Consistent Growth Equity Picks - BỘ NỘI VỤ
Sentiment Recap: Will Cingulate Inc. stock gain from lower inflation2025 Major Catalysts & High Accuracy Swing Entry Alerts - moha.gov.vn
Who’s Hired? Alvotech Promotes McClellan To COO - Citeline News & Insights
Is There NearTerm Timing Risk on India Glycols Limited StockPrice Momentum Alerts & Big Gains Low Investment - earlytimes.in
Press Release: Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
Is Cingulate Inc. Equity Warrant stock dividend yield sustainable - newser.com
Zacks Small Cap Lowers Earnings Estimates for Cingulate - Defense World
Cingulate price target lowered to $16 from $17 at Roth Capital - Yahoo Finance
Why Cingulate Inc. Equity Warrant stock remains on buy listsPortfolio Return Report & Safe Entry Zone Identification - newser.com
Will breakout in Cingulate Inc. Equity Warrant lead to full recoveryJuly 2025 Trends & Technical Analysis for Trade Confirmation - newser.com
What data driven models say about Cingulate Inc.’s futureMarket Sentiment Report & Short-Term High Return Strategies - newser.com
How Cingulate Inc. stock performs in high volatility markets2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Signal strength of Cingulate Inc. stock in tech scannersWeekly Trend Recap & Real-Time Stock Entry Alerts - newser.com
Will Cingulate Inc. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Capital Efficiency Focused Ideas - newser.com
Published on: 2025-11-19 18:10:29 - newser.com
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth - newser.com
Strategies to average down on Cingulate Inc. Equity Warrant2025 Fundamental Recap & Safe Swing Trade Setup Alerts - newser.com
Is Cingulate Inc. Equity Warrant stock in correction or buying zoneJuly 2025 Levels & AI Based Buy and Sell Signals - newser.com
Roth Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Is Cingulate Inc. stock ready for a breakoutJuly 2025 Recap & Community Verified Trade Signals - newser.com
Published on: 2025-11-19 05:53:07 - newser.com
Can Cingulate Inc. stock sustain revenue growthTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
Cingulate Advances ADHD Treatment CTx-1301 Toward Potential 2026 FDA Approval - citybuzz
Does Cingulate Inc. fit your quant trading modelQuarterly Portfolio Report & Target Return Focused Picks - newser.com
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 - TradingView
Cingulate (NASDAQ: CING) Gains FDA Acceptance of CTx-1301 NDA, Eyes ADHD Launch - Stock Titan
Cingulate Inc Azioni (CING) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):